Tumor cell proliferation inhibitors

A mannose-cyclodextrin composition, derived from natural sources, addresses the cytotoxicity issue of existing antitumor agents by enhancing tumor cell suppression with minimal side effects and improved efficacy.

JP7580700B1Active Publication Date: 2024-11-12MEIS TECH CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024113160
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-07-16
Publication Date
2024-11-12
Estimated Expiration
2044-07-16

AI Technical Summary

Technical Problem

Existing antitumor agents exhibit cytotoxicity to both tumor and normal cells, necessitating a highly safe tumor cell growth inhibitor with minimal cytotoxicity that can effectively suppress tumor cell growth without affecting normal cells.

Method used

A composition containing mannose and cyclodextrin, specifically α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, derived from natural sources like konjac potato, is used to inhibit tumor cell proliferation, enhancing the suppressive effect on tumor cells while minimizing side effects.

Benefits of technology

The mannose-cyclodextrin composition achieves a high tumor cell growth suppressive effect with reduced side effects, even at lower doses, effectively inhibiting tumor cell proliferation and promoting cell death.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007580700000001
    Figure 0007580700000001
  • Figure 0007580700000002
    Figure 0007580700000002
  • Figure 0007580700000003
    Figure 0007580700000003
Patent Text Reader

Abstract

The objective of the present invention is to provide a tumor cell proliferation inhibitor comprising mannose and cyclodextrin for use in the prevention and / or treatment of cancer. [Solution] The present invention relates to a tumor cell proliferation inhibitor containing mannose and cyclodextrin, which is effective for the prevention and / or treatment of cancer. The tumor cell proliferation inhibitor of the present invention has a higher tumor cell proliferation inhibitory effect than mannose alone, and therefore can be ingested or administered in small amounts.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a tumor cell proliferation inhibitor, particularly to a tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, comprising mannose and cyclodextrin. [Background technology]

[0002] According to a survey by the Ministry of Health, Labor and Welfare, the number one cause of death among Japanese people is malignant neoplasms (tumors), far ahead of heart disease, which is the second most common cause. Reflecting this, many recent research results have led to progress in elucidating the mechanisms of tumor development. These research results have revealed that various chemical substances can control the development and growth of tumors, and they are used for medicinal purposes as antitumor agents. However, while the various chemical substances used have strong antitumor effects, they also exhibit cytotoxicity not only to tumor cells but also to normal cells, and side effects are a major problem. Therefore, there is a need for a highly safe tumor cell proliferation agent that has very little cytotoxicity and suppresses the growth of only tumor cells.

[0003] It is well known that tumor cells have an active cellular metabolism. In particular, tumor cells have the property of consuming large amounts of sugar compared to normal cells. Many tumor cells have enhanced glucose uptake, and this property is used in cancer screening, known as PET examination. PET examinations use FDG (fluorodeoxyglucose), which has a structure similar to glucose, to detect FDG accumulated in cells and identify the presence and location of tumor cells. As such, because of the enhanced glucose uptake in tumor cells, research is also being conducted on reactions to monosaccharides other than glucose. For example, mannose is taken up into tumor cells by the same transporter as glucose, but it is known to accumulate in the cells as mannose-6-phosphate and inhibit further metabolism of glucose in glycolysis, the tricarboxylic acid cycle, the pentose phosphate pathway, and sugar chain synthesis. As a result, it has been reported that mannose causes the inhibition of proliferation of many types of tumor cells and promotes cell death in response to major chemotherapy (see, for example, Non-Patent Document 1).

[0004] Mannose can be ingested by ingesting foods containing mannose or mannose itself, but β-mannose, one of the anomers of mannose, has a unique bitter taste, and a composition that combines mannose with dietary fiber (cyclodextrin) to suppress this unpleasant taste has been proposed (see Patent Document 1). Furthermore, a method for enhancing the anticancer activity of a water extract of Ashwagandha leaves by using cyclodextrin has also been proposed (see Patent Document 2). [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2011-254749 A [Patent Document 2] International Publication No. 2015 / 115512 [Non-patent literature]

[0006] [Non-Patent Document 1] Pablo Sierra Gonzalez, et. al., “Mannose impairs tumor growth and enhances chemotherapy” NATURE, vol 563, 719-723 (2018) Summary of the Invention [Problem to be solved by the invention]

[0007] Orally administered mannose is absorbed from the small intestine and delivered to the whole body through the bloodstream, where it acts on various cells, but since it does not accumulate specifically in tumor cells, it is necessary to ingest large amounts of mannose to increase the mannose concentration in the whole body. Ingestion of large amounts of mannose has been reported to cause diarrhea and vaginal hot flashes as side effects in some cases.

[0008] In addition, it is known that some additives affect the stability and effect of active ingredients, and since Patent Document 1 focuses on suppressing the bitterness of the composition of cyclodextrin and mannose, it does not describe or suggest the tumor cell proliferation inhibitory effect of the composition. Patent Document 2 describes that a composition obtained by mixing an aqueous extract of Ashwagandha leaves with cyclodextrin has high anticancer activity, but since the mechanisms of action of the aqueous extract of Ashwagandha leaves and mannose on tumor cells are different, the technology in the patent document may not necessarily be applicable to mannose.

[0009] It is known that cyclodextrin can be useful in preparing pharmaceutical substances according to the dosage form of the pharmaceutical, but it is also well recognized in the pharmaceutical industry that it is not effective for all substances. For example, the aforementioned Patent Document 2 describes that the anticancer activity is improved by combining a drug with cyclodextrin, but International Publication No. 2007 / 026869 and JP-A-2024-520888 describe that the combined effect of a drug and cyclodextrin is not high.

[0010] Therefore, an object of the present invention is to provide a tumor cell proliferation inhibitor containing mannose for use in the prevention and / or treatment of cancer, which exhibits a high tumor cell proliferation inhibitory effect even at a small dose. [Means for solving the problem]

[0011] Means for Solving the Problems The present inventors have conducted extensive research to achieve the above object, and as a result have discovered that a composition containing cyclodextrin and mannose has a strong inhibitory effect on tumor cell proliferation, thereby completing the present invention.

[0012] That is, the present invention provides the following (1) to ( 7 ) is the gist of this paper. (1) A tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, comprising mannose and cyclodextrin. The tumor cell proliferation inhibitor, wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin. . (2) The tumor cell proliferation inhibitor according to (1), wherein the mannose is derived from at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them. (3) The tumor cell proliferation inhibitor according to (2), wherein the glucomannan is derived from konjac root. (4) The tumor cell proliferation inhibitor described in (1), wherein the cancer is a cancer of the digestive system. (5) The tumor cell proliferation inhibitor according to (1), wherein the cancer is colon cancer. (6) (1) A tumor cell proliferation inhibitor comprising the tumor cell proliferation inhibitor according to the present invention. For inhibiting tumor cell proliferation Medicines or quasi-drugs. (7) (1) A tumor cell proliferation inhibitor comprising the tumor cell proliferation inhibitor according to the present invention. For inhibiting tumor cell proliferation Food and drink composition. Effect of the Invention

[0013] The tumor cell proliferation inhibitor of the present invention contains mannose and cyclodextrin and can be used for the prevention and / or treatment of cancer. Since it has a higher tumor cell proliferation inhibitory effect than administration of mannose alone, it can be expected to be effective even with a small amount of administration. Furthermore, by using mannose derived from a natural product, it can be safely ingested or administered. [Brief description of the drawings]

[0014] [Figure 1] Inhibitory effect of a composition of mannose derived from konjac yam and gamma-cyclodextrin on tumor cell proliferation [Diagram 2] Inhibitory effect of a composition of mannose derived from konjac yam and gamma-cyclodextrin on tumor cell proliferation [Diagram 3] Antitumor cell proliferation effect of palm kernel meal-derived mannose and α-cyclodextrin composition DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0015] The present invention will be described in detail below. The mannose used in the present invention may be of any origin, and may be D- or L-form. Examples of mannose include mannose obtained by hydrolyzing a raw material containing mannose, such as mannan, glucomannan, or galactomannan, which are constituent sugars of natural products, with an acid, an alkali, an enzyme, or supercritical (subcritical) water; mannose obtained by isomerizing fructose using mannose isomerase as an enzyme; mannose obtained by isomerizing glucose using glucose isomerase and mannose isomerase as enzymes; mannose obtained by epimerizing glucose by heating using a catalyst containing a metal such as molybdic acid; fractions thereof; mixtures thereof; and commercially available mannose. Among these, from the viewpoint of safety, mannose obtained by hydrolyzing at least one selected from mannan, glucomannan, galactomannan, and natural products containing them is preferred.

[0016] When producing mannose from natural products, mannan, glucomannan, galactomannan, or natural products containing them as constituent sugars are not particularly limited as long as they contain mannan, glucomannan, or galactomannan as constituent sugars, and examples thereof include coconut, palm and its oil extraction residue (copra meal, palm kernel meal, etc.), ivory palm (seed), konjac root and its processed products (rough flour, refined flour, flying powder, etc.), guar beans and its processed products (guar gum, etc.), coffee beans or their extraction residue (coffee grounds), locust beans and its processed products (carob powder, locust bean gum, etc.). Among these, copra meal, palm kernel meal, or konjac root and their processed products are preferred, and konjac root and their processed products are more preferred, from the viewpoint of containing a large amount of the constituent sugars and from the viewpoint of low cost. The natural product may be used as a raw material as it is, or may be purified. A mixture of them may also be used.

[0017] In the present invention, when the above-mentioned natural products are subjected to enzymatic treatment, the enzyme is not particularly limited as long as it has an activity of acting on at least one selected from the group consisting of mannan, glucomannan, galactomannan, and natural products containing them to release monosaccharides, but for example, enzymes that act on the main chain of hemicellulose to release monosaccharides, such as mannanase, galactomannanase, glucomannanase, mannosidase, α-xylidase, xyloglucanase, arabinanase, β-xylosidase, xylanase, α-arabinofuranosidase, cellulase, etc., are preferred. Among them, mannanase, mannosidase, galactomannanase, and other mannan-decomposing enzymes are preferred.

[0018] The reaction conditions for releasing mannose by reacting the enzyme with mannan, glucomannan, galactomannan, or natural products containing these as constituent sugars can be selected as optimal conditions according to each enzyme. The reaction temperature is preferably performed under conditions that do not inactivate the enzyme, and is, for example, 30 to 70°C, preferably 40 to 60°C, and more preferably 50 to 60°C. The reaction time depends on conditions such as the amount of enzyme used, but is usually preferably set between 3 hours and 72 hours for operational reasons. Furthermore, the reaction pH depends on the type of enzyme used, and is, for example, preferably pH 2 to 9, more preferably pH 2.5 to 8, and more preferably pH 3 to 6.

[0019] Mannose decomposed from natural products with acids, alkalis, enzymes, supercritical (subcritical) water, etc. may be purified to further increase the purity of mannose. Purification can be performed by known methods such as decolorization with bone charcoal, activated carbon, carbonation, adsorption resin, magnesia method, etc., and desalting and deacidification with ion exchange resins, ion exchange membranes, electrodialysis, etc. The combination of purification methods and purification conditions may be appropriately selected depending on the amounts of pigments, salts, acids, etc. in the mannose-containing reaction solution and other factors. The form of the mannose of the present invention is not particularly limited, and examples thereof include an aqueous solution containing mannose, a powder, etc. To obtain a powder, known techniques such as solid-liquid separation, resin purification, membrane purification, concentration, spray drying, freeze drying, crystallization, etc. From the viewpoint of ease of handling, a powder is preferred. Mannose exists as stereoisomers (anomers) of α-type and β-type mannose, and generally exists in an aqueous solution as mannopyranose, where the anomers are converted to each other and the α-type and β-type are in equilibrium. The mannose of the present invention preferably has an α-type ratio of more than 50% to the total mannose. A known measurement method can be used to measure the α-type.

[0020] Cyclodextrin is an oligosaccharide in which glucose units are linked in a ring by α-1,4 bonds, and is also called cyclic oligosaccharide. Depending on the number of glucose units, it is called α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, and the properties such as the cavity size of the ring structure and solubility in water vary depending on the type. These properties are used for various purposes such as improving the bioavailability of drugs, stabilizing various dyes and functional food ingredients, suppressing unpleasant tastes, and solubilizing poorly water-soluble substances.

[0021] The cyclodextrin used in the tumor cell proliferation inhibitor of the present invention is not particularly limited, and may be α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, or a derivative thereof. A mixture of these may also be used. Examples of the derivative include branched cyclodextrin and chemically modified cyclodextrin. Examples of branched cyclodextrin include glycosylated cyclodextrin in which a sugar side chain is bonded to cyclodextrin by an enzymatic reaction, more specifically, monosaccharide- or disaccharide-modified cyclodextrin such as glucosyl-cyclodextrin, maltosyl-cyclodextrin, galactosyl-cyclodextrin, and mannosyl-cyclodextrin. Examples of chemically modified cyclodextrin include partially methylated cyclodextrin, hydroxypropylated cyclodextrin, sulfobutyl etherified cyclodextrin, acetylated cyclodextrin, and monochlorotriazinyl cyclodextrin. In the present invention, it is preferable to use α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin, and α-cyclodextrin or γ-cyclodextrin is particularly preferable.

[0022] Mannose and cyclodextrin may be mixed or blended as they are, or a composition containing mannose and cyclodextrin may be obtained by adding a 5-30% aqueous solution or suspension of cyclodextrin to an aqueous solution or powder of mannose, and stirring at room temperature or with heating for several minutes to several tens of hours. The composition obtained here is in the form of an aqueous solution, but may be powdered by freeze-drying, spray-drying, dehydration, or other methods. If necessary, the powdered composition may be granulated.

[0023] The amounts of mannose and cyclodextrin to be used can be determined in a manner that is convenient for product design, but generally, it is preferable that the amount of cyclodextrin be 1 to 900 parts by weight, more preferably 10 to 400 parts by weight, and even more preferably 110 to 300 parts by weight, per 100 parts by weight of mannose.

[0024] The tumor cell proliferation inhibitor of the present invention is used for the prevention and / or treatment of cancer. The use for the prevention and / or treatment of cancer means use for at least one of the following purposes: suppression of cancer progression in a patient suffering from cancer, suppression of cancer or tumor growth, prevention of cancer onset, and prevention of cancer recurrence. The types of cancers that are the subject of the present invention are not particularly limited, but include cancers of the digestive system (e.g., colorectal cancer (including colon cancer, colon adenocarcinoma, and rectal cancer), oral cancer, pharyngeal cancer, esophageal cancer, stomach cancer, liver cancer, gallbladder cancer, biliary tract cancer, spleen cancer, small intestine cancer, duodenal cancer, pancreatic cancer, and liver cancer), cancers of the nervous system (e.g., brain tumors and cervical cancer), cancers of the musculoskeletal system (e.g., sarcoma, osteosarcoma, and myeloma), cancers of the urinary system (e.g., bladder cancer and kidney cancer), and cancers of the reproductive system (e.g., breast cancer, uterine cancer, ovarian cancer, testicular cancer, and prostate cancer). , respiratory system cancer (e.g., lung cancer), hematopoietic system cancer (e.g., leukemia such as acute or chronic myeloid leukemia, acute promyelocytic leukemia, acute or chronic lymphocytic leukemia, malignant lymphoma (lymphosarcoma), angiosarcoma, multiple myeloma, myelodysplastic syndrome, primary myelofibrosis, hemangiopericytoma), thyroid cancer, parathyroid cancer, tongue cancer, malignant melanoma, mast cell tumor, cutaneous histiocytoma, lipoma, hair follicle tumor, skin papilloma, sebaceous adenoma, basal cell carcinoma, etc. Among these, application to digestive system cancer is preferred, and application to colon cancer is more preferred.

[0025] The dosage of the tumor cell proliferation inhibitor of the present invention can be appropriately adjusted taking into consideration the purpose of use, the subject of administration, the gender, age, weight, and stage of progression of cancer of the subject. This dosage varies depending on various conditions, so in some cases a small dosage or number of administrations is sufficient, and in other cases a large dosage or number of administrations is required. The administration regime may be a single administration or frequent administration, but frequent administration is preferred because the effect is sustained if the administration is continued. The concentration of mannose to be administered is preferably 2.5 mM to 200 mM, more preferably 4 mM to 150 mM.

[0026] The dosage form of the tumor cell proliferation inhibitor of the present invention is not particularly limited, and may be, for example, oral administration preparations (tablets, coated tablets, powders, granules, capsules, liquids, etc.), airway administration preparations, intraperitoneal administration preparations, intravenous administration preparations, injections, suppositories, patches, ointments, etc., with oral administration preparations, airway administration preparations, or intravenous administration preparations being preferred. Intravenous administration preparations include intravenous injection preparations and drip intravenous injection preparations. In humans, oral administration preparations or intravenous administration preparations are preferred.

[0027] For preparation, the tumor cell proliferation inhibitor of the present invention may be mixed with non-toxic, inactive, medicamentically acceptable excipients, such as solid, semi-solid or liquid diluents, dispersants, fillers and carriers, as necessary.Furthermore, within the range that does not impair the effects of the present invention, stabilizers, preservatives, pH adjusters, binders, disintegrants, surfactants, lubricants, flow enhancers, flavorings, colorants, flavoring preservatives, media, physiological saline, and other medicinal drugs may be included as additives. EXAMPLES

[0028] The present invention will be specifically described with reference to the following examples, but the present invention is not limited to these.

[0029] <Production of mannose derived from konjac root> The enzyme reaction was started by adding 10 mL of ion-exchanged water containing 25 mg of mannanase (Amano Enzyme Co., Ltd., Mannanase BGM "Amano") dissolved therein to 1 g of glucomannan (refined flour) refined from konjac yam. After 48 hours of enzyme treatment at 58°C, the enzyme was inactivated at 96°C for 10 minutes. After filtering using filter paper (No. 5C) to remove water-insoluble matter, the mixture was concentrated using a rotary evaporator to produce a sugar solution with a mannose concentration of 40 g / 100 g.

[0030] <Production of mannose derived from palm kernel meal> 22 mL of water and 8 mL of 1M sulfuric acid were added to 10 g of palm kernel meal (Cargill) to adjust the pH to 0.9, and then prehydrolysis treatment was performed at 90°C for 4 hours. After cooling, 3 mL of 1M sodium hydroxide was added to adjust the pH to 3.6, followed by suction filtration and water washing with 50 mL of water. The washed palm kernel meal was collected, and 24 mL of water and 1M sulfuric acid were added to adjust the pH to 3.6, followed by addition of 0.03 g of the enzyme cellulosin GM5 (mannanase, HBI, unit number: 10,000 unit / g), and shaking for 48 hours at 60°C to perform the enzyme reaction, followed by enzyme inactivation at 100°C for 10 minutes. The obtained raw sugar liquid was filtered through activated carbon to obtain a filtrate.

[0031] The obtained filtrate was desalted with 10 mL of strong acid cation exchange resin (Mitsubishi Chemical: PK216) and 10 mL of weakly basic anion exchange resin (Mitsubishi Chemical: WA30), and then concentrated under reduced pressure using an evaporator. The obtained crude product was crystallized with ethanol to obtain powdered mannose. The obtained powdered mannose was dissolved in water and measured by the following method, and the purity of the mannose in this powder was 99%. (Method for measuring the purity of mannose) Equipment: Differential refractive index detector (SHIMADZU Prominence) Column: Aminex HPX-87P (BIO RAD, 300 mm L x 7.8 mm ID) Mobile phase: water, flow rate: 0.6 ml / min, column temperature: 60°C Sample concentration: 5% aqueous solution, sample volume: 10 μL

[0032] (Example 1 and Example 2) In a 500 mL beaker, 40 g of γ-cyclodextrin (manufactured by Cyclochem) and 200 g of ion-exchanged water were added and completely dissolved, and then 60 g of the konjac yam-derived mannose sugar solution (60 g x 40 g / 100 g = 24 g mannose) obtained above was added and stirred with a magnetic stirrer for 1 hour. The aqueous solution was placed in a freeze dryer and dried. Next, using colon cancer spheroid HC73T strain (owned by Kyoto University), the reactivity to the colon cancer spheroid was analyzed by image analysis using the composition of konjac yam-derived mannose and γ-cyclodextrin obtained above. All experiments were performed three independent times. The colon cancer spheroids were derived from colon cancer patients. The above spheroids that had been frozen and stored were thawed and cultured to obtain an appropriate cell amount. The medium used was Advanced DMEM / F12 (Thermo Fisher), 5% FBS, 10 μM Y27632, 1 μM SB431542, 50 ng / ml EGF, 100 ng / ml FGF-basic, 100 units / ml penicillin, 0.1 mg / ml streptomycin, 2 mM L-glutamine, 5 g / ml Plasmocin (Invivogen, San Diego, CA). Cells for drug sensitivity testing were seeded into 96-well plates (TPP_96F) at 800 cells / well in 4 wells. The composition of konjac yam-derived mannose and γ-cyclodextrin obtained above was added to the medium so that mannose was 5 mM (Example 1) and 25 mM (Example 2). The day after seeding was designated Day 0, and on Day 3 images were taken using a Cell3 imager duos [SCREEN holdings, model CC-8000, software ver.1.6 Rev.2.0.1]. Using Manual Focus mode, 61% of the center of the well was set as the imaging range (a size that would fit the entire gel within the range), and continuous cross-sectional images were taken at 15 points every 50 μm in the z-axis direction, and output as fully focused images. The reaction was started by changing the medium on Day 0. After that, the culture was continued without changing the medium until the end of the experiment. The imaging interval was made to be approximately constant.Using the Measure function of the analysis software [SCREEN holdings, software ver.1.6 Rev.2.0.1], the program was applied to the spheroid image data to calculate the area value. Furthermore, the volume data was calculated from the calculated area value using the program software R. When calculating the volume data, a program was used that calculates the radius from the area, calculates the volume of the sphere from the radius value, and calculates the total volume value per well. The volume ratio was calculated from the volume value Day3 / Day0, and the ratio of each concentration was calculated and compared when the control was set to 1. The volume ratio (Day3 / Day0) of each data point was calculated from the obtained volume data. A t-test was used to test for significant differences with the control group. A p value of less than 0.05 was considered to indicate a significant difference. The results are shown in Figure 1 (Example 1) and Figure 2 (Example 2). The vertical axis GEI in the figure stands for growth effect index.

[0033] (Comparative Example 1 and Comparative Example 3) The same test was carried out using colon cancer spheroids, except that the composition of konjac yam-derived mannose and γ-cyclodextrin in Examples 1 and 2 was replaced with γ-cyclodextrin alone. The results are shown in Figure 1 (Comparative Example 1) and Figure 2 (Comparative Example 3).

[0034] (Comparative Example 2 and Comparative Example 4) The same test was carried out using colon cancer spheroids, except that the composition of konjac root-derived mannose and gamma-cyclodextrin in Example 1 was replaced with 5 mM (Comparative Example 2) and 25 mM (Comparative Example 4) of konjac root-derived mannose alone. The results are shown in Figure 1 (Comparative Example 2) and Figure 2 (Comparative Example 4).

[0035] As is clear from the results of Figures 1 and 2, when the tumor cell proliferation inhibitory effects of Example 1, Comparative Example 1, and Comparative Example 2 were compared, it was observed that the composition of konjac yam-derived mannose and gamma-cyclodextrin in Example 1 had a stronger tumor cell proliferation inhibitory effect than either of them administered alone. Furthermore, a similar tendency was observed for Example 2 and Comparative Examples 3 and 4, in which the mannose addition concentration was increased to 25 mM, and it was observed that the composition of konjac yam-derived mannose and gamma-cyclodextrin had a much stronger tumor cell proliferation inhibitory effect than either of them administered alone.

[0036] Example 3 In a 500 mL beaker, 30 g of α-cyclodextrin (manufactured by CycloChem) and 300 g of ion-exchanged water were added and completely dissolved, and then 20 g of the palm kernel meal-derived mannose powder obtained above was added and stirred with a magnetic stirrer for 1 hour. The aqueous solution was placed in a freeze dryer and dried. Except for replacing the composition of konjac yam-derived mannose and γ-cyclodextrin in Example 2 with a composition of palm kernel meal-derived mannose and α-cyclodextrin, a test was carried out using the same colon cancer spheroids. The results are shown in Figure 3. The concentration of mannose added to the cells was 25 mM.

[0037] Comparative Example 5 30 g of dextrin (Pinex No. 2, Matsutani Chemical Co., Ltd.) and 300 g of ion-exchanged water were added to a 500 mL beaker and completely dissolved, and then 20 g of the palm kernel meal-derived mannose powder obtained above was added and stirred with a magnetic stirrer for 1 hour. The aqueous solution was placed in a freeze dryer and dried. The same test was carried out using colon cancer spheroids, except that the composition of palm kernel meal-derived mannose and α-cyclodextrin in Example 3 was replaced with a composition of palm kernel meal-derived mannose and dextrin. The results are shown in Figure 3. The concentration of mannose added to the cells was 25 mM.

[0038] Comparative Example 6 The same test was carried out using colon cancer spheroids, except that the composition of palm kernel meal-derived mannose and α-cyclodextrin in Example 3 was replaced with only the palm kernel meal-derived mannose prepared above. The results are shown in Figure 3. The concentration of mannose added to the cells was 25 mM.

[0039] As is clear from the results of FIG. 3, when the tumor cell proliferation inhibitory effects of Example 3, Comparative Example 5, and Comparative Example 6 were compared, it was observed that the composition of palm kernel meal-derived mannose and α-cyclodextrin in Example 3 had a stronger tumor cell proliferation inhibitory effect than the composition of palm kernel meal-derived mannose and dextrin and the composition of palm kernel meal-derived mannose alone. It was observed that the composition of mannose and cyclodextrin had a much stronger tumor cell proliferation inhibitory effect than each of them alone or compositions other than cyclodextrin. Therefore, it is possible to expect an effect even with a small amount of administration. Furthermore, by using mannose derived from a natural product, it can be safely ingested or administered.

Claims

1. A tumor cell proliferation inhibitor for use in the prevention and / or treatment of cancer, comprising mannose and a cyclodextrin, wherein the cyclodextrin is α-cyclodextrin, β-cyclodextrin or γ-cyclodextrin.

2. The tumor cell proliferation inhibitor according to claim 1, wherein the mannose is derived from at least one selected from the group consisting of mannan, glucomannan, galactomannan and natural products containing them.

3. The tumor cell proliferation inhibitor according to claim 2, wherein the glucomannan is derived from konjac root.

4. The tumor cell proliferation inhibitor according to claim 1, wherein the cancer is a digestive system cancer.

5. The tumor cell proliferation inhibitor according to claim 1, wherein the cancer is colon cancer.

6. A pharmaceutical or quasi-drug for inhibiting tumor cell proliferation, comprising the tumor cell proliferation inhibitor according to claim 1.

7. A food and drink composition for inhibiting tumor cell proliferation, comprising the tumor cell proliferation inhibitor according to claim 1.

Citation Information

Patent Citations

  • Mannose-containing composition

    JP2011254749A

  • Method for preparing water extract of ashwagandha leaves which has enhanced Anti-cancer activity utilizing cyclodextrin, and pharmaceutical composition containing ashwagandha leaves

    WO2015115512A1